Lopinavir 400 mg/ritonavir 100 mg + Efavirenz
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acquired Immune Deficiency Syndrome
Conditions
Acquired Immune Deficiency Syndrome
Trial Timeline
Oct 1, 2008 → Jan 1, 2011
NCT ID
NCT00775606About Lopinavir 400 mg/ritonavir 100 mg + Efavirenz
Lopinavir 400 mg/ritonavir 100 mg + Efavirenz is a approved stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00775606. Target conditions include Acquired Immune Deficiency Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00775606 | Approved | Terminated |
Competing Products
20 competing products in Acquired Immune Deficiency Syndrome